Key result
Repeated surgery, chemotherapy, and targeted therapy linked to ~13-year survival in recurrent retroperitoneal liposarcoma.
Why the study?
Retroperitoneal liposarcoma is a rare tumor, and cases exhibiting prolonged survival alongside numerous recurrences are exceptionally rare.
Case Report (n=1)
Demonstrates the potential for long-term survival in recurrent retroperitoneal liposarcoma using a combination of cytoreductive surgery, chemotherapy, and targeted therapy.
May support repeated resections in select recurrent cases; hypothesis-generating and leaves generalizability open.
Retroperitoneal liposarcoma (RPLS) is a rare tumor that occurs in the retroperitoneal region and accounts for ~0.2% of all malignant tumor incidence. The present study describes the treatment of a surviving patient with RPLS that recurred five times in 13 years. This case has a long survival time and numerous relapses, which is a rare occurrence. The 40-year-old female patient was admitted to Shaoxing Second Hospital (Shaoxing, China) with an abdominal mass. Abdominal computed tomography (CT) scan revealed multiple liposarcoma recurrences in the abdominal, pelvic and retroperitoneal areas. As the diagnosis of RPLS was the fifth recurrence, cytoreductive surgery was performed and post-operative pathology suggested mixed liposarcoma. The patient underwent six cycles of doxorubicin and ifosfamide regimen chemotherapy and targeted therapy with anlotinib following surgery; no evidence of disease progression was found on abdominal CT scan during follow-up. The present study also reviewed the literature in terms of the clinical diagnosis, treatment, pathological characteristics and similar cases of liposarcoma with the aim of improving diagnosis and treatment.
No takes yet. Share an insight, caveat, or question.
Qiu et al. (2023) conducted a case report in Retroperitoneal liposarcoma (n=1). Surgical resection, chemotherapy, and targeted therapy was evaluated on Survival and disease progression. A 40-year-old female patient with retroperitoneal liposarcoma achieved a survival time of over 13 years despite experiencing five recurrences, managed through repeated surgical resections, chemotherapy, and targeted therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: